Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report

• Published in: Vaccine Vol. 26; no. 51; pp. 6587 - 6591
• Main Authors: But, David Yiu-Kuen, Lai, Ching-Lung, Lim, Wei-Ling, Fung, James, Wong, Danny Ka-Ho, Yuen, Man-Fung
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 02.12.2008; Elsevier; Elsevier Limited
• Subjects: Allergy and Immunology; Antigens; Applied microbiology; Biological and medical sciences; Child; Child, Preschool; Deoxyribonucleic acid; DNA; Dose-Response Relationship, Immunologic; Female; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; HBV infection; Hepatitis; Hepatitis B - immunology; Hepatitis B - prevention & control; Hepatitis B Antibodies - blood; Hepatitis B Antibodies - immunology; Hepatitis B Surface Antigens - blood; Hepatitis B Vaccines - administration & dosage; Hepatitis B Vaccines - immunology; Hepatitis B virus; Human viral diseases; Humans; Immune system; Immunization Schedule; Immunization, Secondary; Immunogenicity; Immunologic Memory; Infant; Infections; Infectious diseases; Male; Medical sciences; Microbiology; Prospective Studies; Studies; Vaccination; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, DNA - administration & dosage; Vaccines, DNA - immunology; Viral diseases; Viral hepatitis; Yeast; Taiwan; Immunogenicity; Vaccination; HBV infection; Human; Infection; Viral hepatitis B; Booster vaccination; Viral disease; Digestive diseases; Hepatic disease; Vaccine; Child
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2008.09.034

Abstract Long-term immunogenicity and efficacy of HBV vaccination with different regimens of HBV vaccines (A: 2-dose recombinant vs. B: 3-dose recombinant vs. C: 3-dose plasma-derived vaccines) without booster dose were examined in 318 Chinese children. Geometric mean titer (GMTs) of anti-HBs of group A subjects was significantly lower than that of groups B and C subjects at years 1, 5, 10 and 15. At year 22, the proportion of subjects with anti-HBs ≥ 10 mIU/mL for groups A, B and C were 35.3%, 76.5% and 52.4%, respectively ( p < 0.05 between groups A and B) in 55 subjects. In the 22 years study period, none was found to be HBsAg positive, and 72 subjects had ≥1 episodes of anamnestic response. In conclusion, the 3-dose regimens have a better long-term immunogenicity. In terms of protection against HBV infection, the 2-dose and 3-dose vaccines had equal efficacies.